Passage Bio, Inc. (PASG)
4.52
+0.19
(+4.39%)
USD |
NASDAQ |
Aug 28, 16:00
4.57
+0.05
(+1.11%)
Pre-Market: 20:00
Passage Bio Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.4897 |
| December 31, 2025 | 1.280 |
| September 30, 2025 | 0.782 |
| June 30, 2025 | 0.6464 |
| March 31, 2025 | 0.5377 |
| December 31, 2024 | 0.4159 |
| September 30, 2024 | 0.3551 |
| June 30, 2024 | 0.2888 |
| March 31, 2024 | 0.2525 |
| December 31, 2023 | 0.2363 |
| September 30, 2023 | 0.21 |
| June 30, 2023 | 0.1778 |
| March 31, 2023 | 0.1582 |
| December 31, 2022 | 0.1346 |
| September 30, 2022 | 0.1216 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.1107 |
| March 31, 2022 | 0.0979 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ARS Pharmaceuticals, Inc. | 7.727 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 25.18M |
| Total Liabilities (Quarterly) | 20.72M |
| Shareholders Equity (Quarterly) | 4.456M |
| Current Ratio | 1.215 |
| Net Debt Paydown Yield | 31.99% |